Global MDMA-assisted Therapy Market

MDMA-assisted Therapy Comprehensive Study by Type (DMT,, Peyote,, Ayahuasca,, Ibogaine., Others chemical compounds which include ketamine, MDMA, and LSD), Application (PTSD, Eating disorders, including anorexia nervosa restricting subtype (AN-R) and binge-eating disorder, Anxiety disorders, including anxiety in adults with autism), Therapy (Cognitive Behavioural Therapy, Dialectical Behaviour Therapy, Exposure Therapy, Group Therapy, Interpersonal Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospital, Clinics, Diagnostic Centres, Others) Players and Region - Global Market Outlook to 2030

MDMA-assisted Therapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
PTSD is a common and debilitating condition with enormous social and economic costs that affects hundreds of millions of people each year. PTSD develops after a traumatic event such as a serious accident, injuries, or war. Memories can manifest as flashbacks or nightmares, forcing some people to relive terrifying events. There is no medication that can treat PTSD, but some medications can help with symptoms. This is where MDMA Therapy arises. MDMA is a psychoactive drug that acts as a stimulant and releases chemicals in your brain to give you energy, heighten your senses, and increase emotions such as self-awareness and empathy. MDMA -assisted therapy helps to treat PTSD Patients.

AttributesDetails
Study Period2019-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledNuminus Wellness (Canada), ATAI Life Sciences (Germany), Seelos Therapeutics (United States), Awakn Life Sciences (Canada), Field Trip Health (Canada), Cybin (Canada), Novamind (Canada) and Mount Sinai Health System (United States)


Segment Analysis
AMA Research have segmented the market of Global MDMA-assisted Therapy market by Type, Application and Region.

On the basis of geography, the market of MDMA-assisted Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Trend
Emergence of Psychedelic Medicine

Market Drivers
Growing Demand for Antidepressants and Increase in Number of Autistic Adults

Opportunities
Rising Investment in Healthcare Sector and Increasing Government Initiatives for MDMA Therapy Awareness

Restraints
  • High Cost of MDMA Drugs and Therapy


In addition to the aforementioned factor, Growing Demand for Antidepressants is expected to propel the growth of the market over the forecast period.

Competitive Landscape
The demand for MDMA-assisted Therapy is increasing. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position. Players are expected to focus on the creation of new compounds, which would likely drive the worldwide market forward over the forecast period.
The key Players profiled in the study are Numinus Wellness (Canada), ATAI Life Sciences (Germany), Seelos Therapeutics (United States), Awakn Life Sciences (Canada), Field Trip Health (Canada), Cybin (Canada), Novamind (Canada) and Mount Sinai Health System (United States). A lot of Canada players are profiled in the research study indicating a strong market dependence.

Report Objectives / Segmentation Covered

By Type
  • DMT,
  • peyote,
  • ayahuasca,
  • ibogaine.
  • Others chemical compounds which include ketamine, MDMA, and LSD
By Application
  • PTSD
  • eating disorders, including anorexia nervosa restricting subtype (AN-R) and binge-eating disorder
  • anxiety disorders, including anxiety in adults with autism
By Therapy
  • Cognitive Behavioural Therapy
  • Dialectical Behaviour Therapy
  • Exposure Therapy
  • Group Therapy
  • Interpersonal Therapy
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User
  • Hospital
  • Clinics
  • Diagnostic Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand for Antidepressants
      • 3.2.2. Increase in Number of Autistic Adults
    • 3.3. Market Challenges
      • 3.3.1. Risk of MDMA Overdose
      • 3.3.2. Lack of Awareness in Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Emergence of Psychedelic Medicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global MDMA-assisted Therapy, by Type, Application, Therapy, Distribution Channel, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global MDMA-assisted Therapy (Value)
      • 5.2.1. Global MDMA-assisted Therapy by: Type (Value)
        • 5.2.1.1. DMT,
        • 5.2.1.2. Peyote,
        • 5.2.1.3. Ayahuasca,
        • 5.2.1.4. Ibogaine.
        • 5.2.1.5. Others chemical compounds which include ketamine, MDMA, and LSD
      • 5.2.2. Global MDMA-assisted Therapy by: Application (Value)
        • 5.2.2.1. PTSD
        • 5.2.2.2. Eating disorders, including anorexia nervosa restricting subtype (AN-R) and binge-eating disorder
        • 5.2.2.3. Anxiety disorders, including anxiety in adults with autism
      • 5.2.3. Global MDMA-assisted Therapy by: Therapy (Value)
        • 5.2.3.1. Cognitive Behavioural Therapy
        • 5.2.3.2. Dialectical Behaviour Therapy
        • 5.2.3.3. Exposure Therapy
        • 5.2.3.4. Group Therapy
        • 5.2.3.5. Interpersonal Therapy
        • 5.2.3.6. Others
      • 5.2.4. Global MDMA-assisted Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global MDMA-assisted Therapy (Price)
      • 5.3.1. Global MDMA-assisted Therapy by: Type (Price)
  • 6. MDMA-assisted Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Numinus Wellness (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ATAI Life Sciences (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Seelos Therapeutics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Awakn Life Sciences (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Field Trip Health (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cybin (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novamind (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mount Sinai Health System (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global MDMA-assisted Therapy Sale, by Type, Application, Therapy, Distribution Channel, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global MDMA-assisted Therapy (Value)
      • 7.2.1. Global MDMA-assisted Therapy by: Type (Value)
        • 7.2.1.1. DMT,
        • 7.2.1.2. Peyote,
        • 7.2.1.3. Ayahuasca,
        • 7.2.1.4. Ibogaine.
        • 7.2.1.5. Others chemical compounds which include ketamine, MDMA, and LSD
      • 7.2.2. Global MDMA-assisted Therapy by: Application (Value)
        • 7.2.2.1. PTSD
        • 7.2.2.2. Eating disorders, including anorexia nervosa restricting subtype (AN-R) and binge-eating disorder
        • 7.2.2.3. Anxiety disorders, including anxiety in adults with autism
      • 7.2.3. Global MDMA-assisted Therapy by: Therapy (Value)
        • 7.2.3.1. Cognitive Behavioural Therapy
        • 7.2.3.2. Dialectical Behaviour Therapy
        • 7.2.3.3. Exposure Therapy
        • 7.2.3.4. Group Therapy
        • 7.2.3.5. Interpersonal Therapy
        • 7.2.3.6. Others
      • 7.2.4. Global MDMA-assisted Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global MDMA-assisted Therapy (Price)
      • 7.3.1. Global MDMA-assisted Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. MDMA-assisted Therapy: by Type(USD Million)
  • Table 2. MDMA-assisted Therapy DMT, , by Region USD Million (2018-2023)
  • Table 3. MDMA-assisted Therapy Peyote, , by Region USD Million (2018-2023)
  • Table 4. MDMA-assisted Therapy Ayahuasca, , by Region USD Million (2018-2023)
  • Table 5. MDMA-assisted Therapy Ibogaine. , by Region USD Million (2018-2023)
  • Table 6. MDMA-assisted Therapy Others chemical compounds which include ketamine, MDMA, and LSD , by Region USD Million (2018-2023)
  • Table 7. MDMA-assisted Therapy: by Application(USD Million)
  • Table 8. MDMA-assisted Therapy PTSD , by Region USD Million (2018-2023)
  • Table 9. MDMA-assisted Therapy Eating disorders, including anorexia nervosa restricting subtype (AN-R) and binge-eating disorder , by Region USD Million (2018-2023)
  • Table 10. MDMA-assisted Therapy Anxiety disorders, including anxiety in adults with autism , by Region USD Million (2018-2023)
  • Table 11. MDMA-assisted Therapy: by Therapy(USD Million)
  • Table 12. MDMA-assisted Therapy Cognitive Behavioural Therapy , by Region USD Million (2018-2023)
  • Table 13. MDMA-assisted Therapy Dialectical Behaviour Therapy , by Region USD Million (2018-2023)
  • Table 14. MDMA-assisted Therapy Exposure Therapy , by Region USD Million (2018-2023)
  • Table 15. MDMA-assisted Therapy Group Therapy , by Region USD Million (2018-2023)
  • Table 16. MDMA-assisted Therapy Interpersonal Therapy , by Region USD Million (2018-2023)
  • Table 17. MDMA-assisted Therapy Others , by Region USD Million (2018-2023)
  • Table 18. South America MDMA-assisted Therapy, by Country USD Million (2018-2023)
  • Table 19. South America MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 20. South America MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 21. South America MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 22. South America MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 23. South America MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 24. Brazil MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 25. Brazil MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 26. Brazil MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 27. Brazil MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 28. Brazil MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 29. Argentina MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 30. Argentina MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 31. Argentina MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 32. Argentina MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 33. Argentina MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 34. Rest of South America MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 35. Rest of South America MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 36. Rest of South America MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 37. Rest of South America MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 38. Rest of South America MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 39. Asia Pacific MDMA-assisted Therapy, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 41. Asia Pacific MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 42. Asia Pacific MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 43. Asia Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 44. Asia Pacific MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 45. China MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 46. China MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 47. China MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 48. China MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 49. China MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 50. Japan MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 51. Japan MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 52. Japan MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 53. Japan MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 54. Japan MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 55. India MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 56. India MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 57. India MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 58. India MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 59. India MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 60. South Korea MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 61. South Korea MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 62. South Korea MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 63. South Korea MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 64. South Korea MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 65. Australia MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 66. Australia MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 67. Australia MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 68. Australia MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 69. Australia MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 75. Europe MDMA-assisted Therapy, by Country USD Million (2018-2023)
  • Table 76. Europe MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 77. Europe MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 78. Europe MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 79. Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 80. Europe MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 81. Germany MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 82. Germany MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 83. Germany MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 84. Germany MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 85. Germany MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 86. France MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 87. France MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 88. France MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 89. France MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 90. France MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 91. Italy MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 92. Italy MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 93. Italy MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 94. Italy MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 95. Italy MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 96. United Kingdom MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 97. United Kingdom MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 98. United Kingdom MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 99. United Kingdom MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 100. United Kingdom MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 101. Netherlands MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 102. Netherlands MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 103. Netherlands MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 104. Netherlands MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 105. Netherlands MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 106. Rest of Europe MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 107. Rest of Europe MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 108. Rest of Europe MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 109. Rest of Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 110. Rest of Europe MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 111. MEA MDMA-assisted Therapy, by Country USD Million (2018-2023)
  • Table 112. MEA MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 113. MEA MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 114. MEA MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 115. MEA MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 116. MEA MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 117. Middle East MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 118. Middle East MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 119. Middle East MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 120. Middle East MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 121. Middle East MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 122. Africa MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 123. Africa MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 124. Africa MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 125. Africa MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 126. Africa MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 127. North America MDMA-assisted Therapy, by Country USD Million (2018-2023)
  • Table 128. North America MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 129. North America MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 130. North America MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 131. North America MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 132. North America MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 133. United States MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 134. United States MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 135. United States MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 136. United States MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 137. United States MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 138. Canada MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 139. Canada MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 140. Canada MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 141. Canada MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 142. Canada MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 143. Mexico MDMA-assisted Therapy, by Type USD Million (2018-2023)
  • Table 144. Mexico MDMA-assisted Therapy, by Application USD Million (2018-2023)
  • Table 145. Mexico MDMA-assisted Therapy, by Therapy USD Million (2018-2023)
  • Table 146. Mexico MDMA-assisted Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 147. Mexico MDMA-assisted Therapy, by End User USD Million (2018-2023)
  • Table 148. MDMA-assisted Therapy: by Type(USD/Units)
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. MDMA-assisted Therapy: by Type(USD Million)
  • Table 158. MDMA-assisted Therapy DMT, , by Region USD Million (2025-2030)
  • Table 159. MDMA-assisted Therapy Peyote, , by Region USD Million (2025-2030)
  • Table 160. MDMA-assisted Therapy Ayahuasca, , by Region USD Million (2025-2030)
  • Table 161. MDMA-assisted Therapy Ibogaine. , by Region USD Million (2025-2030)
  • Table 162. MDMA-assisted Therapy Others chemical compounds which include ketamine, MDMA, and LSD , by Region USD Million (2025-2030)
  • Table 163. MDMA-assisted Therapy: by Application(USD Million)
  • Table 164. MDMA-assisted Therapy PTSD , by Region USD Million (2025-2030)
  • Table 165. MDMA-assisted Therapy Eating disorders, including anorexia nervosa restricting subtype (AN-R) and binge-eating disorder , by Region USD Million (2025-2030)
  • Table 166. MDMA-assisted Therapy Anxiety disorders, including anxiety in adults with autism , by Region USD Million (2025-2030)
  • Table 167. MDMA-assisted Therapy: by Therapy(USD Million)
  • Table 168. MDMA-assisted Therapy Cognitive Behavioural Therapy , by Region USD Million (2025-2030)
  • Table 169. MDMA-assisted Therapy Dialectical Behaviour Therapy , by Region USD Million (2025-2030)
  • Table 170. MDMA-assisted Therapy Exposure Therapy , by Region USD Million (2025-2030)
  • Table 171. MDMA-assisted Therapy Group Therapy , by Region USD Million (2025-2030)
  • Table 172. MDMA-assisted Therapy Interpersonal Therapy , by Region USD Million (2025-2030)
  • Table 173. MDMA-assisted Therapy Others , by Region USD Million (2025-2030)
  • Table 174. South America MDMA-assisted Therapy, by Country USD Million (2025-2030)
  • Table 175. South America MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 176. South America MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 177. South America MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 178. South America MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 179. South America MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 180. Brazil MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 181. Brazil MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 182. Brazil MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 183. Brazil MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 184. Brazil MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 185. Argentina MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 186. Argentina MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 187. Argentina MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 188. Argentina MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 189. Argentina MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 190. Rest of South America MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 191. Rest of South America MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 192. Rest of South America MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 193. Rest of South America MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 194. Rest of South America MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 195. Asia Pacific MDMA-assisted Therapy, by Country USD Million (2025-2030)
  • Table 196. Asia Pacific MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 197. Asia Pacific MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 198. Asia Pacific MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 199. Asia Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 200. Asia Pacific MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 201. China MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 202. China MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 203. China MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 204. China MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 205. China MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 206. Japan MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 207. Japan MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 208. Japan MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 209. Japan MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 210. Japan MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 211. India MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 212. India MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 213. India MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 214. India MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 215. India MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 216. South Korea MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 217. South Korea MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 218. South Korea MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 219. South Korea MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 220. South Korea MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 221. Australia MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 222. Australia MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 223. Australia MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 224. Australia MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 225. Australia MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 226. Rest of Asia-Pacific MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 227. Rest of Asia-Pacific MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 228. Rest of Asia-Pacific MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 229. Rest of Asia-Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 230. Rest of Asia-Pacific MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 231. Europe MDMA-assisted Therapy, by Country USD Million (2025-2030)
  • Table 232. Europe MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 233. Europe MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 234. Europe MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 235. Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 236. Europe MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 237. Germany MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 238. Germany MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 239. Germany MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 240. Germany MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 241. Germany MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 242. France MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 243. France MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 244. France MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 245. France MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 246. France MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 247. Italy MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 248. Italy MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 249. Italy MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 250. Italy MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 251. Italy MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 252. United Kingdom MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 253. United Kingdom MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 254. United Kingdom MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 255. United Kingdom MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 256. United Kingdom MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 257. Netherlands MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 258. Netherlands MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 259. Netherlands MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 260. Netherlands MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 261. Netherlands MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 262. Rest of Europe MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 263. Rest of Europe MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 264. Rest of Europe MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 265. Rest of Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 266. Rest of Europe MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 267. MEA MDMA-assisted Therapy, by Country USD Million (2025-2030)
  • Table 268. MEA MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 269. MEA MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 270. MEA MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 271. MEA MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 272. MEA MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 273. Middle East MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 274. Middle East MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 275. Middle East MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 276. Middle East MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 277. Middle East MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 278. Africa MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 279. Africa MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 280. Africa MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 281. Africa MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 282. Africa MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 283. North America MDMA-assisted Therapy, by Country USD Million (2025-2030)
  • Table 284. North America MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 285. North America MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 286. North America MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 287. North America MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 288. North America MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 289. United States MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 290. United States MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 291. United States MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 292. United States MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 293. United States MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 294. Canada MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 295. Canada MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 296. Canada MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 297. Canada MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 298. Canada MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 299. Mexico MDMA-assisted Therapy, by Type USD Million (2025-2030)
  • Table 300. Mexico MDMA-assisted Therapy, by Application USD Million (2025-2030)
  • Table 301. Mexico MDMA-assisted Therapy, by Therapy USD Million (2025-2030)
  • Table 302. Mexico MDMA-assisted Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 303. Mexico MDMA-assisted Therapy, by End User USD Million (2025-2030)
  • Table 304. MDMA-assisted Therapy: by Type(USD/Units)
  • Table 305. Research Programs/Design for This Report
  • Table 306. Key Data Information from Secondary Sources
  • Table 307. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global MDMA-assisted Therapy: by Type USD Million (2018-2023)
  • Figure 5. Global MDMA-assisted Therapy: by Application USD Million (2018-2023)
  • Figure 6. Global MDMA-assisted Therapy: by Therapy USD Million (2018-2023)
  • Figure 7. South America MDMA-assisted Therapy Share (%), by Country
  • Figure 8. Asia Pacific MDMA-assisted Therapy Share (%), by Country
  • Figure 9. Europe MDMA-assisted Therapy Share (%), by Country
  • Figure 10. MEA MDMA-assisted Therapy Share (%), by Country
  • Figure 11. North America MDMA-assisted Therapy Share (%), by Country
  • Figure 12. Global MDMA-assisted Therapy: by Type USD/Units (2018-2023)
  • Figure 13. Global MDMA-assisted Therapy share by Players 2023 (%)
  • Figure 14. Global MDMA-assisted Therapy share by Players (Top 3) 2023(%)
  • Figure 15. Global MDMA-assisted Therapy share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Numinus Wellness (Canada) Revenue, Net Income and Gross profit
  • Figure 18. Numinus Wellness (Canada) Revenue: by Geography 2023
  • Figure 19. ATAI Life Sciences (Germany) Revenue, Net Income and Gross profit
  • Figure 20. ATAI Life Sciences (Germany) Revenue: by Geography 2023
  • Figure 21. Seelos Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 22. Seelos Therapeutics (United States) Revenue: by Geography 2023
  • Figure 23. Awakn Life Sciences (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Awakn Life Sciences (Canada) Revenue: by Geography 2023
  • Figure 25. Field Trip Health (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Field Trip Health (Canada) Revenue: by Geography 2023
  • Figure 27. Cybin (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Cybin (Canada) Revenue: by Geography 2023
  • Figure 29. Novamind (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Novamind (Canada) Revenue: by Geography 2023
  • Figure 31. Mount Sinai Health System (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mount Sinai Health System (United States) Revenue: by Geography 2023
  • Figure 33. Global MDMA-assisted Therapy: by Type USD Million (2025-2030)
  • Figure 34. Global MDMA-assisted Therapy: by Application USD Million (2025-2030)
  • Figure 35. Global MDMA-assisted Therapy: by Therapy USD Million (2025-2030)
  • Figure 36. South America MDMA-assisted Therapy Share (%), by Country
  • Figure 37. Asia Pacific MDMA-assisted Therapy Share (%), by Country
  • Figure 38. Europe MDMA-assisted Therapy Share (%), by Country
  • Figure 39. MEA MDMA-assisted Therapy Share (%), by Country
  • Figure 40. North America MDMA-assisted Therapy Share (%), by Country
  • Figure 41. Global MDMA-assisted Therapy: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Numinus Wellness (Canada)
  • ATAI Life Sciences (Germany)
  • Seelos Therapeutics (United States)
  • Awakn Life Sciences (Canada)
  • Field Trip Health (Canada)
  • Cybin (Canada)
  • Novamind (Canada)
  • Mount Sinai Health System (United States)
Additional players considered in the study are as follows:
COMPASS Pathways PLC (United Kingdom) , MindMed (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 242 Pages 70 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global MDMA-assisted Therapy Market Quantitative research analysis
Global MDMA-assisted Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The MDMA-assisted Therapy market is expected to see a CAGR of % during projected year 2023 to 2030.
Top performing companies in the Global MDMA-assisted Therapy market are Numinus Wellness (Canada), ATAI Life Sciences (Germany), Seelos Therapeutics (United States), Awakn Life Sciences (Canada), Field Trip Health (Canada), Cybin (Canada), Novamind (Canada) and Mount Sinai Health System (United States), to name a few.
is dominating segment of MDMA-assisted Therapy Market in 2023.

Know More About Global MDMA-assisted Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Transplant Rejection Treatment Comprehensive Study by Type (Hyperacute Transplant Rejection, Acute Transplant Rejection, Chronic Transplant Rejection), Drugs (Antirejection Medicines, Corticosteroids...
$ 3500
Non-ablative Lasers Comprehensive Study by Type (Non Fractional Lasers, Conventional Lasers), Application (Skin Pigmentation, Scars, Rhytides, Photo Aging), Technology (Radiofrequency Systems, Mid-I...
$ 3650
Posterior Cervical Spine System Comprehensive Study by Type (Anterior Cervical Fusion, Posterior Cervical Fusion), End-users (Hospitals, Ambulatory Surgical Centers, Specialty Orthopedic Clinics) Pla...
$ 3500
Hospital Acquired Disease Testing- Comprehensive Study by Type (Urinary Tract Infection, Pneumonia, Bloodstream, Surgical Site, Other), Drugs (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs),...
$ 3800
Pendred Syndrome Comprehensive Study by Type (Sensorineural hearing loss,, Conductive hearing loss, Mixed hearing loss), Application (Hearing aids for children with the condition.), Treatment (Radioa...
$ 3800
Mandibular Implants Comprehensive Study by End-users (Hospitals, Dental Clinics, Academic & Research Institutes), Material (Titanium Implants, Zirconium Implants), Dental Implants (Two-Stage Dental I...
$ 3800